Navigation Links
Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation
Date:10/27/2015

QUEBEC CITY, Oct. 27, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis & Co., two leading independent proxy research and advisory firms, have published reports recommending that the Company's shareholders vote FOR a special resolution authorizing the consolidation of the issued and outstanding common shares of the Company at a consolidation ratio of between 8-for-1 and 100-for-1 (the "Share Consolidation") at a special meeting of shareholders to be held on Monday, November 16, 2015 at 9:30 a.m. (Eastern time) (the "Meeting").

"I am pleased that ISS and Glass Lewis, two leading independent research and advisory firms, validate the views of our Board of Directors that the proposed share consolidation would be in the best interest of the Company and its shareholders," stated David A. Dodd, Chairman, President and CEO of the Company.  "We believe that the Share Consolidation is necessary in order to avoid the delisting of our Common Shares from The NASDAQ Capital Market and to improve our capital structure", Mr. Dodd concluded. 

The Management Information Circular (the "Circular") sent to shareholders contains, among other things, details concerning the Share Consolidation, reasons that the Company's Board of Directors recommends the Share Consolidation, requirements for the Share Consolidation to be implemented and the procedure for receiving new shares if the Share Consolidation is implemented, as well as the procedures for voting at the meeting and other related matters.  Shareholders are urged to carefully review the Circular and accompanying materials as they contain important information regarding the Share Consolidation and its consequences to Shareholders.  A copy of the Circular is available on SEDAR at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission's website at www.sec.gov.

The Board of Directors UNANIMOUSLY recommends that Shareholders vote FOR the Share Consolidation.

YOUR VOTE IS IMPORTANT.  VOTE TODAY!

A proxy form or voting instruction form will accompany the Meeting materials you receive by mail. Instructions on how to vote, which vary depending on whether you are a registered or beneficial shareholder of the Company are provided in the Circular and the proxy form or voting instruction form.

If you have any questions or require more information with regard to the procedures for voting, please contact Laurel Hill Advisory Group, the Company's proxy solicitation agent, toll free at 1-877-452-7184, collect at 416-304-0211 or by email at assistance@laurelhill.com.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health.  For more information, visit www.aezsinc.com.

 


'/>"/>
SOURCE Aeterna Zentaris Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
2. Leading Photonics and Laser Researchers to Present Latest Work at SPIE Optics + Optoelectronics
3. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
4. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
5. Biotrial, a Successful Leading CRO, Continues to Expand its Activities, Creating a Unique Neuroscience Pool of Talent and Capabilities: Biotrial Neuroscience
6. Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services
7. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
8. Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Announces the Highly Anticipated Release of Medrio 8.1 with iPad Support
9. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
10. Tata Partners with Tel Aviv University to Fund Leading Edge Innovations for Accelerated Commercialization
11. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):